Eyal Kalo

Eyal Kalo earned his Ph.D from the Weizmann Institute of Science following an extensive research around mutant p53 protein and its contribution to cancer initiation and progression.

Eyal completed his studies at 2010 and joined the biotechnology industry where he gained expertise in the development of cell-based and cell-free assays for drug discovery, diagnostic and skin care applications. In parallel, Eyal acquired an extensive knowledge and experience in project management. He was responsible for driving the development of various projects from concept to launch in the field of Pharmaceutical, Medical devices, Nutraceutical and Cosmetics.